King Luther Capital Management Corp Sells 5,220 Shares of Charles River Laboratories International, Inc. $CRL

King Luther Capital Management Corp trimmed its holdings in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 10.0% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 46,980 shares of the medical research company’s stock after selling 5,220 shares during the period. King Luther Capital Management Corp owned 0.10% of Charles River Laboratories International worth $7,350,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Hantz Financial Services Inc. raised its position in shares of Charles River Laboratories International by 11.2% during the 3rd quarter. Hantz Financial Services Inc. now owns 793 shares of the medical research company’s stock valued at $124,000 after acquiring an additional 80 shares during the last quarter. Rothschild Investment LLC increased its holdings in Charles River Laboratories International by 82.4% in the third quarter. Rothschild Investment LLC now owns 186 shares of the medical research company’s stock valued at $29,000 after purchasing an additional 84 shares during the last quarter. Patriot Financial Group Insurance Agency LLC lifted its stake in Charles River Laboratories International by 4.2% in the third quarter. Patriot Financial Group Insurance Agency LLC now owns 2,120 shares of the medical research company’s stock valued at $332,000 after buying an additional 85 shares during the period. DekaBank Deutsche Girozentrale boosted its holdings in Charles River Laboratories International by 1.2% during the second quarter. DekaBank Deutsche Girozentrale now owns 7,142 shares of the medical research company’s stock worth $1,072,000 after buying an additional 86 shares during the last quarter. Finally, Resona Asset Management Co. Ltd. grew its position in shares of Charles River Laboratories International by 17.5% during the 3rd quarter. Resona Asset Management Co. Ltd. now owns 584 shares of the medical research company’s stock worth $86,000 after buying an additional 87 shares during the period. 98.91% of the stock is owned by institutional investors.

Analysts Set New Price Targets

CRL has been the topic of several recent analyst reports. Citigroup lifted their price objective on shares of Charles River Laboratories International from $200.00 to $265.00 and gave the stock a “buy” rating in a research note on Friday, January 16th. Bank of America raised shares of Charles River Laboratories International from a “neutral” rating to a “buy” rating and set a $225.00 price target for the company in a report on Monday, December 15th. Robert W. Baird set a $193.00 price objective on Charles River Laboratories International in a research note on Thursday. Wall Street Zen raised Charles River Laboratories International from a “hold” rating to a “buy” rating in a research note on Saturday, February 7th. Finally, JPMorgan Chase & Co. raised their price target on Charles River Laboratories International from $165.00 to $190.00 and gave the stock a “neutral” rating in a research report on Monday, December 15th. Ten analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $205.92.

Charles River Laboratories International Stock Performance

Shares of Charles River Laboratories International stock opened at $163.66 on Friday. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.29 and a quick ratio of 1.10. The firm has a market cap of $8.06 billion, a price-to-earnings ratio of -55.29, a price-to-earnings-growth ratio of 4.69 and a beta of 1.63. The stock’s 50-day moving average is $200.84 and its 200-day moving average is $179.33. Charles River Laboratories International, Inc. has a one year low of $91.86 and a one year high of $228.88.

Charles River Laboratories International (NYSE:CRL) last released its earnings results on Wednesday, February 18th. The medical research company reported $2.39 EPS for the quarter, beating the consensus estimate of $2.33 by $0.06. The firm had revenue of $994.23 million for the quarter, compared to analysts’ expectations of $986.98 million. Charles River Laboratories International had a positive return on equity of 15.60% and a negative net margin of 3.59%.The business’s quarterly revenue was down .8% compared to the same quarter last year. During the same quarter in the previous year, the business posted $2.66 EPS. Charles River Laboratories International has set its FY 2026 guidance at 10.700-11.200 EPS. Equities analysts predict that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current fiscal year.

Key Charles River Laboratories International News

Here are the key news stories impacting Charles River Laboratories International this week:

• Positive Sentiment: Q4 results beat consensus on both EPS and revenue, with management providing a slide deck and call that highlighted margin expansion versus prior quarters — a near‑term catalyst supporting the move higher. Q4 Earnings and Revenues Surpass Estimates
• Positive Sentiment: Management set FY‑2026 EPS guidance roughly in line with or slightly above Street expectations and reiterated confidence in improving demand for drug‑development services — this guidance reduces near‑term forecast uncertainty. Reuters: Charles River forecasts upbeat 2026 profit
• Positive Sentiment: Company announced executive appointments and emphasized cost‑savings, acquisitions and a new CEO strategy that management says will drive ~up to 9% EPS growth and margin expansion — a constructive strategic signal for investors. Executive Appointments
• Neutral Sentiment: Full earnings call transcript and slide deck released; provides detail on segment trends, backlog and timing of biotech demand recovery — useful for adjusting model assumptions but not an immediate directional trigger. Earnings Call Transcript
• Negative Sentiment: Underlying organic growth softened (revenue down ~0.8% YoY) and some coverage flagged flat sales and margin pressures in parts of the business — risks that could cap multiple expansion until growth inflects. Deep Dive: Flat Sales and Margin Pressures
• Negative Sentiment: Several analysts noted the stock dipped intraday last week despite the beat due to concerns around slowing organic demand and mixed segment performance — continued execution risk remains. Stock Down Despite Beat

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.